Clinical trial Recruiting at 1 site Observational Ages 15 and up Women only

Monitoring the safety of UPLIZNA in pregnant women with NMOSD

Official title: An Observational Pregnancy Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® (Inebilizumab-cdon) During Pregnancy

Run by Amgen · NCT05909761 · Data updated 2026-11-12

This study is trying to see how safe the medication UPLIZNA is for pregnant women with Neuromyelitis Optica Spectrum Disorder (NMOSD) by tracking their pregnancies and outcomes over the next 10 years.

More Pregnancy Related trials

Quick facts

Study typeObservational
Ages15 Years and up
SexWomen only
Enrollment60 (estimated)
SponsorAmgen
Industry-sponsored
Locations1 site (Aurora, Colorado)
StatusRecruiting
StartedJanuary 15, 2027
Main results expectedOctober 31, 2032
Study endsOctober 31, 2032
Registry record updatedOctober 29, 2026
Trial IDNCT05909761 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are women of reproductive potential with a confirmed or suspected diagnosis of NMOSD who have been exposed to UPLIZNA during pregnancy.

Probably not a fit

Patients who are not pregnant or have not been exposed to UPLIZNA during pregnancy or within the preceding six months may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to monitor female participants diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) who have been exposed to UPLIZNA during pregnancy or within six months prior to conception. Participants will voluntarily report their pregnancies, and the study will collect data on pregnancy outcomes, potential confounding factors, and other relevant information over a minimum duration of 10 years. The schedule of office visits and treatment regimens will be determined by the participants' healthcare providers.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the safety of UPLIZNA during pregnancy, potentially guiding treatment decisions for women with NMOSD.

How similar studies have gone: While there may be limited data on similar studies, the observational nature of this study is crucial for understanding the implications of UPLIZNA exposure during pregnancy, making it a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Provide informed consent
* Are a female of reproductive potential with a confirmed or suspected diagnosis of NMOSD
* Have been exposed to UPLIZNA during pregnancy as defined by receipt of any dose during pregnancy or within 6 months preceding conception

Note: Other Protocol Defined Inclusion/Exclusion Criteria Apply

Where it's running

  • University of Colorado Denver
    Aurora, Colorado, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.